Suzuki Shigeru, Koga Masafumi
Shigeru Suzuki, Department of Pediatrics, Asahikawa Medical University, Asahikawa 078-8510, Hokkaido, Japan.
World J Diabetes. 2014 Apr 15;5(2):198-208. doi: 10.4239/wjd.v5.i2.198.
Neonatal diabetes mellitus (NDM) is a type of diabetes mellitus caused by genetic abnormality which develops in insulin dependent state within 6 mo after birth. HbA1c is widely used in clinical practice for diabetes mellitus as the gold standard glycemic control indicator; however, fetal hemoglobin (HbF) is the main hemoglobin in neonates and so HbA1c cannot be used as a glycemic control indicator in NDM. Glycated albumin (GA), another glycemic control indicator, is not affected by HbF. We reported that GA can be used as a glycemic control indicator in NDM. However, it was later found that because of increased metabolism of albumin, GA shows an apparently lower level in relation to plasma glucose in NDM; measures to solve this problem were needed. In this review, we outlined the most recent findings concerning glycemic control indicators in neonates or NDM.
新生儿糖尿病（NDM）是一种由基因异常引起的糖尿病，在出生后6个月内于胰岛素依赖状态下发病。糖化血红蛋白（HbA1c）作为血糖控制的金标准指标，在糖尿病临床实践中被广泛应用；然而，胎儿血红蛋白（HbF）是新生儿的主要血红蛋白，因此HbA1c不能用作NDM的血糖控制指标。糖化白蛋白（GA）作为另一种血糖控制指标，不受HbF影响。我们曾报道GA可作为NDM的血糖控制指标。然而，后来发现由于白蛋白代谢增加，在NDM中GA相对于血浆葡萄糖水平明显较低；需要采取措施解决这一问题。在本综述中，我们概述了有关新生儿或NDM血糖控制指标的最新研究结果。
